Coronary microvascular dysfunction beyond the spectrum of chronic coronary syndromes
- Authors: Marta Belmonte, MD1*, Alberto Foà, MD, PhD2*, Pasquale Paolisso, MD, PhD3, Luca Bergamaschi, MD2, Emanuele Gallinoro, MD, PhD3, Alberto Polimeni, MD4,5, Roberto Scarsini, MD, PhD6, Saverio Muscoli, MD, PhD7, Sara Amicone, MD2, Antonio De Vita, MD8, Angelo Villano, MD8, Francesco Angeli, MD2, Matteo Armillotta, MD2, Vincenzo Sucato, MD9, Saverio Tremamunno, MD10, Doralisa Morrone, MD, PhD11, Ciro Indolfi, MD, PhD12,13, Pasquale Perrone Filardi, MD, PhD1, Flavio Ribichini MD, PhD6, Gaetano Antonio Lanza, MD8, Alaide Chieffo, MD14,15, Emanuele Barbato, MD, PhD16 and Carmine Pizzi, MD2 on behalf of the Coronary Physiopathology and Microcirculation Working Group of the Italian Society of Cardiology (SIC).
- Publication year: 2024
- Type: Articolo in rivista
- OA Link: http://hdl.handle.net/10447/661953
Abstract
The prevalence of coronary microvascular dysfunction (CMD) beyond the spectrum of chronic coronary syndromes (CCS) is non-negligible, pertaining to pathophysiological and therapeutical implications. Thanks to the availability of accurate and safe non-invasive technique, CMD can be identified as a key player in heart failure, cardiomyopathies, Takotsubo syndrome, aortic stenosis. While CMD is widely recognized as a cause of myocardial ischemia leading to a worse prognosis even in the absence of obstructive coronary artery disease, the characterization of CMD patterns beyond CCS might provide valuable insights on the underlying disease progression, being potentially a “red flag” of adverse cardiac remodelling and a major determinant of response to therapy and outcomes. In this review, we aimed to provide an overview of the latest evidence on the prevalence, mechanistic and prognostic implications of CMD beyond the spectrum of CCS (i.e. heart failure, cardiomyopathies, Takotsubo syndrome, aortic stenosis)